Several new prospects for preparation of T cell vaccines have been suggested based on the identification and characterization of MHC-associated peptides. Synthetic peptides that correspond to these T cell epitopes may represent ideal subunits for safe vaccines. However, synthetic peptides are poor immunogens because of their small molecular size and very short serum half-life. To circumvent these disadvantages, a variety of recombinant proteins that carry short immunogenic epitopes have been described, and these so-called antigenized molecules represent a new generation of subunit vaccines (5-9). Genetically engineered Ab molecules can function as such delivery systems for T cell peptides (10, 11) and have the advantage of being self-proteins devoid of the side effects sometimes associated with microbial vaccines and, moreover, have a long half-life compared with synthetic peptides.
O
ver recent years, considerable efforts have been directed toward the development of efficient vaccines aimed to stimulate T cells. Effector CD4 ϩ T cells are central in this regard because they regulate B cells and are essential for induction of CD8 ϩ CTL responses through both cytokine secretion (1) and dendritic cell sensitization (2) . CD4 ϩ T cells mainly recognize peptides derived from the processing of extracellular antigens by antigen-presenting cells (APCs), presented in association with MHC class II molecules. Targeting of antigen to APCs by coupling to APC-specific Abs increases CD4 ϩ T cell activation, probably because of increased uptake of antigen (3, 4) .
Several new prospects for preparation of T cell vaccines have been suggested based on the identification and characterization of MHC-associated peptides. Synthetic peptides that correspond to these T cell epitopes may represent ideal subunits for safe vaccines. However, synthetic peptides are poor immunogens because of their small molecular size and very short serum half-life. To circumvent these disadvantages, a variety of recombinant proteins that carry short immunogenic epitopes have been described, and these so-called antigenized molecules represent a new generation of subunit vaccines (5) (6) (7) (8) (9) . Genetically engineered Ab molecules can function as such delivery systems for T cell peptides (10, 11) and have the advantage of being self-proteins devoid of the side effects sometimes associated with microbial vaccines and, moreover, have a long half-life compared with synthetic peptides.
Abs are processed by APCs, and short peptides are presented on class II molecules to CD4 ϩ T cells (12, 13) . A series of papers have been published that describe recombinant Abs in which the variable (V) region complementarity-determining region (CDR) 2, CDR3, or both are replaced with various antigenic peptides recognized by B cells (10, (14) (15) (16) , CD8 ϩ T cells (17) (18) (19) , and CD4 ϩ T cells (11, 20, 21) . However, when the peptides are introduced in CDRs of V domains, the Abs lose their antigenbinding specificity. Our strategy is to construct recombinant Abs that carry T cell epitopes in loops in their constant (C) domains, thereby allowing the subsequent addition of APC-specific V regions to the Abs. The loops used resemble CDR loops in that they connect ␤-strands in the ␤-sheets of the Ig C domain.
We have previously shown that loops in the C H 1 domain of human IgG3 can be replaced with the class II-restricted 2
315
T cell epitope, which comprises amino acids 91-101 of the 2 Ig light (L) chain produced by the MOPC315 plasmacytoma. In the original molecule, this epitope encompasses the V region CDR3 loop. Such Ab-peptide chimeras stimulate specific CD4 ϩ T cells both in vitro and in vivo (22, 23) . Targeting of these Abs to B cells increases antigen presentation efficiency in vitro as well as in vivo (23) .
One could argue that the use of an epitope derived from a CDR loop may lead to results that cannot be extended to epitopes that are not loop structures or epitopes derived from non-Ab proteins. To demonstrate the versatility of the strategy, we have introduced three different, well characterized T cell epitopes into human IgG. These are amino acids 110-120 of hemagglutinin (HA) of influenza PR8 virus, amino acids 323-339 of ovalbumin (OVA), and amino acids 46-61 of hen egg lysozyme (HEL). All epitopes have been introduced as substitutions of the sixth loop (L6) in the C H 1 domain. This 4-aa loop corresponds to the CDR3 loop in the V H domain (22) . It is known from x-ray crystallography data that neither the HA, OVA, nor HEL epitope is a loop in its native molecule and, moreover, all are different both in length and secondary structure. Nevertheless, all recombinant Abs are secreted from transfected cells at levels comparable to wild-type (wt) molecules, indicating that the main outline of the C domain framework is maintained. The Abs are internalized and processed by APCs, and the peptides generated stimulate specific T cells. When the Abs are IgD-specific, they are up to 650 times more efficient than nontargeted Abs in activating T cells in vitro, and up to 50,000 times more potent than the corresponding synthetic Abbreviations: APCs, antigen-presenting cells; C, constant; CDR, complementaritydetermining region; Fc␥R, Fc␥ receptor; H, heavy; HA, hemagglutinin; HEL, hen egg lysozyme; L, light; NIP, 4-hydroxy-5-iodo-3-nitrophenacetyl; NP, 4-hydroxy-3-nitrophenacetyl; OVA, ovalbumin; TCR, T cell receptor; Tg, transgenic; V, variable; wt, wild type. § To whom reprint requests should be addressed. E-mail: inger.sandlie@bio.uio.no.
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peptide. In vivo, only the IgD-specific recombinant Abs delivered enough peptide to APCs to activate T cells. Thus, the chimeric Abs stimulate a significantly stronger response than free peptide at equimolar concentrations. Antigens. A synthetic peptide corresponding to amino acid residues 110-120 (SFERFEIFPKE) of HA was a gift from S. Degermann and K. Karjalainen (Basel Institute for Immunology). A synthetic peptide corresponding to amino acid residues 46-61 (NTDGSTDYGILQINSR) of HEL was a gift from R. Germain. OVA protein was purchased from Sigma. A synthetic peptide corresponding to amino acid residues 323-339 (ISQAVHAAHAEINEAGR) of OVA was a gift from B. Fleckenstein (University of Oslo).
Materials and Methods
Ab Constructs. OVA, HEL, and HA peptides were expressed on human IgG3 molecules by substituting the L6 loop in the C H 1 domain. The loops in the domain are numbered consecutively following the linear amino acid sequence. Because each C domain harbors six loops, L6 is the third ''upper'' loop in the domain. The resulting recombinant Ab molecules were denoted L6-OVA, L6-HEL, and L6-HA, respectively.
The design of the molecules is illustrated in Fig. 1 . In brief, a 0.9-kb HindIII-PstI fragment encoding the C H 1 domain was subcloned into M13mp19 and served as template in the in vitro mutagenesis reactions. Site-specific in vitro mutagenesis was performed as described by Kunkel (31) . Reagents for mutagenesis reactions were from Bio-Rad. The mutations were confirmed by sequencing. The mutant C H 1 fragments were ex- changed with the corresponding wt sequence by using HindIII and BglII sites. The resulting mutant C␥3 genes were subcloned as HindIII-BamHI fragments into the vector pLNOH2 (32) . Upstream from the cloning site, this vector contains a cytomegalovirus promoter and originally, the mouse V H gene, V NP . The combination of V NP -containing heavy (H) chains and 1 L chains creates Abs with specificity for the haptens NP (4-hydroxy-3-nitrophenacetyl) and NIP (4-hydroxy-5-iodo-3-nitrophenacetyl).
The cloning of V region genes that confer specificity for mouse IgD (allotype a) has been described (23) . The anti-IgD V H was cloned in pLNOH2, creating a vector encoding the H chain of an IgD-specific IgG3. The wt C␥3 region gene was subsequently exchanged with the mutant C␥3 genes on HindIII-BamHI sites. The anti-IgD V was subcloned upstream from the human C gene in the pLNO vector as described (23) .
Ab Production. To make anti-NIP Abs, pLNOH2 vectors containing mutant ␥3 genes were transfected into the murine plasma cell line J558L by electroporation [BTX (San Diego) apparatus ECM600: Ϸ1 ϫ 10 7 cells, 20 g of DNA, 175 V, 1,300 F, 129 ⍀]. To produce anti-IgD Abs, the pLNOH2 and pLNO vectors with anti-IgD V genes and mutant ␥3 genes were combined to one vector through a BamHI͞BglII cloning step as described (32) and then transfected into NS0 cells by electroporation as explained for J558L cells. Transfected cells were selected in medium containing 800 g͞ml G418 and cloned by limiting dilution. Supernatants from single, G418-resistant colonies were analyzed for Ab secretion after 2-3 wk, by using ELISA as described (33) .
Individual clones were cultured in DMEM͞5% FCS at high density in the miniPERM bioreactor (Heraeus). Anti-NIP Abs were purified from the cell supernatant by affinity chromatography with the hapten NP coupled to AH-Sepharose (Amersham Pharmacia). Antibodies were eluted from the column with 0.2 mM NIP in PBS͞0.02% NaN 3 . Anti-IgD Abs were affinity purified on protein G (Amersham Pharmacia) or protein L (Actigen) columns. Antibodies were eluted from the columns with 0.1 M glycine⅐HCl (pH 2.7) and rapidly neutralized to avoid aggregation. Eluates were concentrated and dialyzed against PBS and finally against regular growth medium. The purified Abs were analyzed for the presence of aggregates by size exclusion chromatography using Superdex 200 HR 30͞10 (Amersham Pharmacia). This gel filtration regularly showed only a trace of aggregates (Ͻ1%). per well). After 24 h, supernatant was withdrawn and IL-2 production was measured as described above, whereas IFN-␥ production was measured in an ELISA as described (34) . (36, 37) . Three mutated H chains were constructed to include HA, OVA, and HEL peptides, respectively. In all cases, the nucleotides encoding the L6 loop in the IgG3 C H 1 gene were deleted and replaced by nucleotide sequences coding for the selected peptide as shown in Fig. 1 . We have earlier shown that this loop is permissive for expression of the 2 315 peptide (22, 23) . Notably, in previous work, the L6 loop was denoted L3 as its position in the C domain corresponds to that of the CDR3 loop in a V domain. The HA, OVA, and HEL mutants were secreted from transfected cells, indicating that the main tertiary structure was maintained, because misfolded proteins are normally retained intracellularly (38) (39) (40) . The functional integrity was confirmed in ELISAs in which microtiter plates were coated with antigen (BSA-NIP) or Abs specific for human ␥ chains. Binding was detected with sheep-anti-human IgG (Fab, Fc, or ␥ chain specific) or sheep-anti-L chains (data not shown). These NIP-specific Abs with HA, OVA, or HEL peptides were denoted ␣NIP.L6-HA, ␣NIP.L6-OVA, and ␣NIP.L6-HEL, respectively.
Results

Construction of Antibodies with
To target the peptides to APCs, the NIP-specific V genes were exchanged with V genes specific for the a allotype of mouse IgD Fig. 2 shows an increase in T cell activation when the chimeric molecules were targeted to B cells. The doseresponse curves show that ␣IgD.L6-HA was Ϸ300-fold more efficient than its nontargeted counterpart in activating the T cells. Anti-IgD molecules with wt H chain C region, ␣IgD.wt, did not elicit any response. Compared with synthetic peptide, ␣IgD.L6-HA was 40,000-50,000 times more efficient than free peptide at equimolar concentrations. 
IgG3 with HEL Peptide Efficiently Stimulates the T Cell Hybridoma 3A9.
Further evidence that Ab molecules can function as carriers for delivery of yet another epitope is presented in Fig. 4 . The Abs used carry the 46-61 epitope from HEL. As APCs we used spleen cells from C3H mice, which have the MHC H-2 k haplotype and express I-A k MHC class II molecules necessary for presentation of the HEL epitope to specific 3A9 hybridoma cells. Both the targeted and the nontargeted Ab are superior immunogens compared with free unconjugated peptide, ␣IgD.L6-HEL being 10,000-15,000 times more efficient than synthetic peptide based on a molar ratio. The experiments also confirm that targeting induces a more vigorous T cell response because ␣IgD.L6-HEL is 100-150 times more efficient than ␣NIP.
L6-HEL.
IgG3 with HA and OVA Peptides Are Targeted to APCs in Vivo and
Enhance T Cell Activation. The recombinant Abs were also tested for their ability to target APCs in vivo. First, the IgD-specific Ab with the HA epitope was compared with its NIP-specific counterpart and with synthetic HA peptide. Preparations of all three molecules were injected i.v. in titrated amounts into BALB͞c mice. After 1.5 h, spleen cells were mixed with HA-specific Vir-2 T cells without any further addition of peptide. Spleen cells from mice injected with 10 Ϫ10 mol (8 g) or more of ␣IgD.L6-HA activated HA-specific Vir-2 T cells as measured by IFN-␥ production (Fig. 5A) , whereas there were no detectable T cell responses after injection of synthetic HA peptide or ␣NIP.L6-HA, even after increasing the amount of injected material 100-fold. Thus, the targeted Ab was at least 100 times more efficient. In a separate experiment, synthetic HA peptide did not induce a response even when 10 production (Fig. 5B) . Again, the recombinant IgD-specific Ab was found to be at least 1,000-fold more efficient than complete OVA protein and 100-fold more efficient than synthetic OVA peptide.
Discussion
Engineered Abs are attractive carriers for antigenic peptides because Ab-peptide fusions stimulate potent and specific immunity (8, 9, 23) . Complete human Abs are likely to be long-lived molecules devoid of side effects and may be given unique specificities. Our main goal is to construct Abs that contain T cell epitopes integrated in their C parts and have V regions with specificity for APCs.
In earlier work (22, 23) , we showed that the 2
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T cell epitope could replace the CDR-like loops L4 and L6 in the C H 1 domain and that the two loop mutants were able to elicit MHC class II-restricted CD4 ϩ T cell responses. In this report, we have extended this concept by inserting a variety of T cell epitopes in the L6 loop in the C H 1 domain. The 2 315 epitope is originally derived from a loop structure, the CDR3 region in an L chain, and might for that reason be more easily grafted in loops than other T cell epitopes. It was therefore important to extend the strategy to other T cell epitopes.
The three epitopes used in this work are all different, in terms of both length and secondary structure in the intact proteins. The HAs of influenza virus are divided into three subtypes, H1, H2, and H3, of which the H3 subtype has been crystallized (42) . The HA-(110-120) epitope used in this study is derived from the H1 subtype. Despite the low degree of homology with the H3 subtype at the level of amino acid sequence (43) , there is a strict conservation between subtypes of many structurally important amino acids. Therefore, it is assumed that the subtypes share many of their structural features as well as a common overall shape (42, 44) . The HA-(110-120)-corresponding sequence in the H3 subtype has a secondary structure defined as a bend ␤-strand ␥-turn (43, 45) . The OVA-(323-339) epitope is composed mostly of amino acids participating in a ␤ ladder (46) , whereas the HEL-(46-61) epitope in its native position in the lysozyme protein has a secondary structure with three turns and two ␤-strands (47) . Despite these differences in secondary structure motifs, the L6 loop is permissive for all epitopes. Furthermore, the peptides were presented to T cells in a specific manner, indicating that they were all cleaved out of the Abs and bound a diversity of class It is known that the flanking residues outside the core sequence of a T cell epitope may influence its processing and presentation (48) (49) (50) (51) (52) . The Ig flanking regions in L6 did not seem to have any negative effect on the presentation of the HA, OVA, or HEL epitope, which agrees with other observations for T cell peptides expressed as integral parts of unrelated proteins (49, 51) . In conclusion, the L6 loop in the C H 1 domain of human ␥3 chains appears to represent a permissive site for grafting a multitude of foreign epitopes without altering the structural integrity of the Ab molecule or the immunogenicity of the peptides.
The efficiency of antigen presentation depends, to a large extent, on the concentration of peptide͞MHC complexes on the APC surface (53) . Thus, by genetically linking the epitopes to APC-specific targeting molecules, the antigen load may be increased, thereby enhancing the antigen uptake, processing, and presentation, and subsequently, increased T cell activation. The use of genetically engineered Abs for delivery of immunogenic peptides has been previously described in an APCtargeting context by Baier and coworkers (9) . They achieved immunotargeting by using IgD or MHC class II-specific Fab fragments with T cell epitopes inserted as C-terminal tails. This procedure may have a disadvantage in that peptides attached to the end of a molecule may be more sensitive to proteases (54) . By including the epitopes as integral parts of the Ab molecule, we anticipated that the peptides would acquire the same half-life as the Ab molecule itself. We have previously shown that targeting of the 2 315 epitope on complete, bivalent Abs to IgD on B cells increases T cell activation 100-10,000 times in vitro and 20-100 times in vivo (23) . The results presented in this study clearly extend this notion because anti-IgD Abs with HA, OVA, or HEL peptides are 150-650 times more efficient than their nontargeted counterparts.
Because a major limitation in the use of synthetic peptide as vaccines is the instability and inherently weak immunogenicity of natural peptides, we show here that targeting of HA, OVA, and HEL epitopes to IgD on the APC dramatically increases the presentation efficiency compared with free peptide, in vitro as well as in vivo. The most striking difference is demonstrated in the experiments with the HA epitope in vitro, in which ␣IgD.L6-HA is up to 40,000-50,000 times more efficient than free HA peptide. After i.v. injection, the targeted Abs induced T cell activation, whereas control Abs, antigenic protein, as well as synthetic peptide did not. In conclusion, we expect that coupling of peptides to Abs specific for receptors on specialized APCs constitutes several major advantages for vaccination.
The peptide can be targeted to the specific subset of cells expressing the relevant receptors. We have chosen IgD on B cells in our model system. In general, B cells are not optimal targets in vivo. This reservation concerns the question of whether B cells are able to activate T cells that are genuinely naïve (55, 56) . However, other candidate molecules may certainly be good targets in vivo. MHC class II or DEC 205 (57), as well as other surface molecules on dendritic cells, are prime candidates, as numerous studies point to dendritic cells as the main APCs in class II-restricted T cell priming in vivo (58, 59) and in vitro (60, 61) .
For further in vivo administration, the Fc regions should preferably be made devoid of effector functions (62) (63) (64) (65) because Fc receptors expressed on peripheral blood cells play an important role in triggering a variety of cytotoxic, phagocytic, and inflammatory functions. The site for binding of IgGs to Fc␥ receptor I (Fc␥RI) is proposed to be Leu-Leu-Gly-Gly-Pro-Ser (EU numbering 234-239), which lies in the lower hinge region (66) . Human IgG4 and mouse IgG2b, which have low or no affinity for Fc␥RI, contain the sequence Phe-Leu-Gly-Gly-ProSer and Leu-Glu-Gly-Gly-Pro-Ser, respectively, at the Fc␥RI-binding site. Recent reports (67, 68) have shown that the lower hinge of Igs is likely to be involved in binding to all Fc receptors. The use of C domain loops for epitope insertion may also allow for the introduction of many epitopes into the same Ab molecule.
Brumeanu et al. (16) and Xiong et al. (20) have shown that an Ab molecule can contain a T and a B cell epitope simultaneously added to the CDR2 and CDR3 loops of the V H domain. Because each C domain in IgG harbors six loops, there are numerous other candidate positions for insertion of epitopes. Accordingly, our long-term aim is to exchange several C region loops simultaneously to create a multivalent vaccine contained within a single Ab molecule.
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